• Moderate to severe rheumatoid arthritis who did not respond adequately to disease-modifying anti-rheumatic drugs, like Methotrexate.

• Giant cell arteritis.

• Polyarticular juvenile idiopathic arthritis (Age >= 2)

• Systemic juvenile idiopathic arthritis (Age >= 2)

• Treatment of Post-menopausal osteoporosis.  Can reduce the incidence of vertebral fractures.

• Prevention of Post-menopausal osteoporosis.

 • Adults with active, moderate-to-severe Ulcerative Colitis who did not respond or could not tolerate a TNF blocker like Remicade OR who did not respond or could not tolerate or become dependent on steroids.

• Adults with active, moderate-to-severe Crohn’s Disease who did not respond or could not tolerate a TNF blocker like Remicade OR who did not respond or could not tolerate or become dependent on steroids.

Patients with congenital deficiency of Alpha-1 proteinase inhibitor and clinical manifestation of emphysema.

Patients with relapsing or primary progressive forms of multiple sclerosis.

• Treatment for Postmenopausal women with osteoporosis at high risk for fracture

• Treatment to increase bone mass in men at high risk for fracture

• Prophylaxis for patients receiving androgen deprivation therapy for nonmetastatic prostate cancer

• Treatment to increase bone mass in women at high risk for fracture

• Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

• Active, moderate-to-severe Crohn’s Disease

• Active, moderate-to-severe Ulcerative Colitis

• Active, moderate-to-severe Rheumatoid Arthritis in conjunction with Methotrexate

• Symptomatic ankylosing spondylitis

• Symptomatic psoriatic arthritis

• Severe plaque psoriasis

• Rheumatoid disorders such as acute gouty arthritis, rheumatoid arthritis

• Allergic states such as intractable allergic asthma, seasonal allergic rhinitis

• Gastrointestinal diseases such as Crohn’s Disease and Ulcerative Colitis

• Hematologic disorders such as idiopathic thrombocytopenia purport

• Neurologic disorders such as acute exacerbations of multiple sclerosis

• Respiratory disorders such as symptomatic sarcoidosis

Relapsing multiple sclerosis

Active, severe Crohn’s Disease

Patients with congenital deficiency of Alpha-1 proteinase inhibitor and clinical manifestation of emphysema.

• Crohn's Disease. Indicated for maintaining clinical response in patients with moderate to severely active disease who had an inadequate response to conventional therapy. 

• Rheumatoid Arthritis. 

• Psoriatic Arthritis.

• Ankylosing Spondylitis. 

• Spondyloarthritis.

• Plaque Psoriasis.

Treatment of iron deficiency anemia in adult patients with chronic kidney disease.

Gout who have not responded to conventional therapy.

• Active, moderate-to-severe rheumatoid arthritis (adults)

• Active, moderate-to-severe polyarticular juvenile idiopathic arthritis (also known as “juvenile rheumatoid arthritis”) (age >= 6)

• Active psoriatic arthritis.

FDA approved since May 2017 for patients with Amyotrophic Lateral Sclerosis (ALS), especially early stage.

• Active, moderate-to-severe rheumatoid arthritis in conjunction with Methotrexate

• Granulomatosis with Polyangiitis

• Microscopic Polyangiitis

• Moderate-to-severe plaque psoriasis

• Active psoriatic arthritis

• Active, moderate-to-severe Crohn’s Disease who either failed or were intolerant to corticosteroids or failed or were intolerant to TNF blockers.

Adults and adolescents (age >= 12) with moderate to severe asthma with positive skin tests for perennial allergens and whose symptoms are not adequately controlled with inhaled corticosteroids.

Patients with active systemic lupus erythematous who are already receiving standard therapy.

Due to various systemic side effects, Cytoxan is not a first-line agent.  Physicians, however, may consider Cytoxan for off-label use in patients with severe autoimmune diseases, including Rheumatoid Arthritis and Multiple Sclerosis, who have not responded to other treatments.

• IgG deficiency disorders such as Common Variable Immunodeficiency.

• Autoimmune disorders such as Idiopathic thrombocytopenia Purpura, Dermatomyositis, Kawasaki disease, Myasthenia Gravis, Multiple sclerosis and Guillain-Barre syndrome.

Patients with relapsing multiple sclerosis who have had inadequate responses to two or more medications for multiple scleroses such as Interferon beta and Copaxone.

Patients with congenital deficiency of Alpha-1 proteinase inhibitor and clinical manifestation of emphysema.

• Treatment & prevention of postmenopausal osteoporosis

• Treatment to increase bone mass in men with osteoporosis

• Treatment and prevention of glucocorticoid-induced osteoporosis

• Treatment of Paget’s disease of bone in men and women.

• Active, moderate-to-severe Rheumatoid Arthritis in conjunction with methotrexate

• Active Psoriatic Arthritis

• Active Ankylosing Spondylitis

• Non-dialysis dependent Chronic Kidney Disease

• Dialysis-Dependent Chronic Kidney Disease (CKD)